Tag: radioligand therapy market opportunity

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Radioligand Therapy Market Growth Potential: How Will Market Size Shift Through 2030?

The radioligand therapy market size has seen rapid growth in recent years. It is anticipated to expand from $6.63 billion in 2025 to $7.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. The historical growth of this market can be attributed to factors such as the limited availability of radioligands, the reliance on conventional cancer therapies, growing awareness of the benefits of targeted therapy, increasing hospital adoption of nuclear medicine techniques, and regulatory approvals for early RLT drugs.

The radioligand therapy market is poised for significant expansion in the coming years. Its market size is projected to reach $10.72 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.0%. This anticipated growth within the forecast period is attributable to several factors, including the ongoing development of novel alpha and beta emitters, the broadening application of combined emission therapies, its integration with precision oncology, an increase in clinical trials targeting neurological and cardiovascular conditions, and rising investments in home care and outpatient RLT services. Prominent trends for the forecast period encompass the increasing adoption of targeted radioligand therapy in oncology, the expansion of alpha and beta emitter-based treatments, the incorporation of radioligand therapy with personalized medicine approaches, growth in hospital and research institution-based RLT programs, and an elevated focus on minimizing side effects while enhancing patient outcomes.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=53629632&type=smp&name=Radioligand%20Therapy%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Radioligand Therapy Market Expansion Drivers: What’s Shaping Future Growth?

The anticipated rise in cancer cases is projected to fuel the expansion of the radioligand therapy market in the future. Cancer is characterized by the unchecked proliferation of aberrant cells, which can infiltrate adjacent tissues and metastasize across the body. The surge in cancer prevalence is attributed to prolonged exposure to environmental contaminants, leading to DNA damage, cellular dysfunction, and the fostering of abnormal cell development. Radioligand therapy offers a treatment for cancer by delivering radiation directly to tumor cells via ligands that attach to specific receptors, thereby reducing damage to healthy tissues while internally eliminating cancerous cells. For example, as reported by the National Health Service (NHS), a government health agency in the UK, in October 2025, new cancer diagnoses totaled 354,820 in 2023, averaging 972 daily. This figure represents an increase of 8,605 compared to 2022. Consequently, the rising occurrence of cancer is a key factor boosting the radioligand therapy market’s growth.

Radioligand Therapy Market Segment Analysis: What Are The Core Market Categories?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

Radioligand Therapy Market Strategic Trends: What Defines The Next Growth Phase?

Major companies operating in the radioligand therapy market are focusing on developing advanced solutions, such as radioligand therapy facilities, to enhance production efficiency and maintain consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. These specialized radioligand therapy centers are designed to handle and deliver radioactive drugs for targeted cancer treatment using advanced imaging systems and radiation shielding, ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This facility received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.

Radioligand Therapy Market Top Companies Driving Competitive Growth

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

View The Full Radioligand Therapy Market Report:

https://thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Radioligand Therapy Market Regional Analysis And Top Geography

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Radioligand Therapy Market Expansion From $7.32 Billion In 2026 To $10.72 Billion In 2030

The radioligand therapy market has seen swift expansion in recent times. Its value is projected to rise from $6.63 billion in 2025 to $7.32 billion by 2026, reflecting a compound annual growth rate (CAGR) of 10.4%. Historically, this growth has been driven by factors such as the scarce supply of radioligands, a dependence on standard cancer treatments, heightened recognition of the advantages offered by targeted therapies, greater integration of nuclear medicine methods in hospitals, and regulatory clearances granted for early radioligand therapy (RLT) drugs.

The radioligand therapy market is projected to experience significant expansion over the coming years, reaching a valuation of $10.72 billion by 2030, driven by a compound annual growth rate (CAGR) of 10.0%. This forecasted growth is fueled by the development of novel alpha and beta emitters, the expansion of combined emission therapies, deeper integration with precision oncology, an increase in clinical trials targeting neurological and cardiovascular conditions, and heightened investment in home care and outpatient radioligand therapy services. Key trends shaping the period include the growing adoption of targeted radioligand therapy in oncology, the broadening of alpha and beta emitter-based treatment options, the incorporation of radioligand therapy into personalized medicine frameworks, the expansion of radioligand therapy programs within hospitals and research institutions, and an intensified focus on minimizing adverse effects while improving patient outcomes.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Radioligand Therapy Market Expansion Supported By Key Demand Factors

The rising prevalence of cancer is anticipated to drive expansion in the radioligand therapy market in the coming years. Cancer is characterized by the unregulated proliferation of abnormal cells, which can infiltrate adjacent tissues and metastasize throughout the body. This increase in cancer cases is driven by prolonged exposure to environmental contaminants that damage DNA, impair cellular processes, and encourage irregular cell growth. Radioligand therapy addresses cancer by delivering radiation directly to tumor cells via ligands that attach to specific receptors, thereby reducing damage to healthy tissue and eliminating cancer cells from within. As an example, in October 2025, the National Health Service (NHS), a government health agency in the UK, reported 354,820 new cancer diagnoses in 2023—an average of 972 per day—representing an increase of 8,605 compared to 2022. Consequently, the growing incidence of cancer is fueling the advancement of the radioligand therapy market.

Radioligand Therapy Market Segments: Where Are The Largest Growth Opportunities?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

Radioligand Therapy Market Growth Trends Influencing Competitive Dynamics

Leading players in the radioligand therapy market are concentrating on developing innovative solutions, such as specialized radioligand therapy facilities, to boost production efficiency and uphold consistent quality and safety standards during the manufacturing and distribution of targeted cancer therapies. These facilities are bespoke centers engineered to manage and administer radioactive drugs for precision cancer treatment, leveraging cutting-edge imaging technologies and radiation shielding while ensuring safety via well-trained staff and rigorous procedures. For example, in January 2024, Novartis AG, a pharmaceutical company headquartered in Switzerland, unveiled the automation of its new large-scale radioligand therapy (RLT) production facility located in Indiana. This plant gained approval from the Food and Drug Administration (FDA) for commercial manufacturing. Spanning 70,000 square feet, it stands as Novartis’s largest and most advanced site dedicated to RLT, designed for efficient, time-sensitive production, and includes provisions for fully automated production lines, facilitating substantial supply increases to address rising patient demand across the United States and Canada.

Radioligand Therapy Market Major Participants And Competitive Dynamics

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

Access The Complete Radioligand Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Radioligand Therapy Market Regional Distribution: Which Areas Drive Market Expansion?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

By 2030, How Much Growth In Market Size Is Expected For The Radioligand Therapy Market?

The radioligand therapy market size has seen rapid growth in recent years. It is expected to grow from $6.63 billion in 2025 to $7.32 billion in 2026, with a compound annual growth rate (CAGR) of 10.4%. The expansion observed in the past can be attributed to factors such as the limited accessibility of radioligands, the previous reliance on conventional cancer treatments, an increasing understanding of the benefits of targeted therapies, the rising adoption of nuclear medicine techniques in hospitals, and the initial regulatory approvals for RLT drugs.

The radioligand therapy market is projected for significant expansion over the coming years, with its valuation reaching $10.72 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This anticipated growth during the forecast period is driven by factors such as the development of new alpha and beta emitters, the broadening of combined emission therapies, their integration with precision oncology, an increase in clinical trials targeting neurological and cardiovascular conditions, and greater investment in home care and outpatient radioligand therapy services. Key trends expected during this period involve the growing acceptance of targeted radioligand therapy for cancer treatment, the expansion of therapies utilizing alpha and beta emitters, the integration of radioligand therapy with personalized medicine strategies, an increase in radioligand therapy programs within hospitals and research institutions, and a heightened emphasis on reducing adverse effects while improving patient results.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Drivers Are Advancing The Radioligand Therapy Market Growth?

The future expansion of the radioligand therapy market is anticipated to be driven by the rising occurrence of cancer. This condition, cancer, is characterized by the unchecked proliferation of atypical cells capable of infiltrating adjacent tissues and disseminating across the body. The surge in cancer cases stems from prolonged exposure to environmental contaminants, which harm DNA, impair cellular processes, and stimulate the development of irregular cell growth. Radioligand therapy offers a treatment for cancer by precisely delivering radiation to tumor cells. It achieves this through ligands that attach to specific receptors, thereby limiting damage to healthy tissues while internally eliminating cancer cells. As an illustration, data from October 2025 by the National Health Service (NHS), a government health agency in the UK, revealed 354,820 new cancer diagnoses in 2023, averaging 972 daily. This figure represents an increase of 8,605 compared to 2022. Consequently, the escalating rate of cancer incidence is a primary factor fueling the expansion of the radioligand therapy market.

Which Segment Divisions Form The Structure Of The Radioligand Therapy Market?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

What Trends Are Shaping The Radioligand Therapy Market Structure?

Leading companies in the radioligand therapy market are focused on developing advanced solutions, such as radioligand therapy facilities, to improve production efficiency and uphold consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. Radioligand therapy facilities are specialized centers crafted to handle and deliver radioactive medications for precise cancer treatment, utilizing advanced imaging systems and radiation shielding, while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility stands as the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.

Which Key Players Are Active In The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc.

Access The Complete Radioligand Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Which Region Holds The Largest Share In The Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Radioligand Therapy Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company

Property Management Service Market Report 2026

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Radioligand Therapy Market Grow Between 2026 And 2030?

The radioligand therapy market has seen considerable growth in recent years. Its size is expected to expand from $6.63 billion in 2025 to $7.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. This historical expansion can be attributed to several factors, including the limited availability of radioligands, reliance on conventional cancer therapies, growing awareness of targeted therapy benefits, increasing hospital adoption of nuclear medicine techniques, and regulatory approvals for early rlt drugs.

The radioligand therapy market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $10.72 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This growth during the forecast period is attributable to the introduction of novel alpha and beta emitters, the expansion of combined emission therapies, integration with precision oncology, an increase in clinical trials for neurological and cardiovascular applications, and greater investment in home care and outpatient rlt services. Prominent trends for the forecast period include the increasing adoption of targeted radioligand therapy in oncology, the broadening of alpha and beta emitter-based therapies, the integration of radioligand therapy with personalized medicine approaches, the expansion of hospital and research institution-based rlt programs, and a heightened focus on minimizing side effects and improving patient outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Key Drivers Are Affecting The Radioligand Therapy Market Development?

The escalating incidence of cancer is projected to stimulate growth within the radioligand therapy market. Cancer is defined as a condition involving the unchecked proliferation of abnormal cells that can infiltrate surrounding tissues and disseminate throughout the body. The rise in cancer cases is attributed to sustained exposure to environmental pollutants, which harm DNA, impair cell function, and foster irregular cell development. Radioligand therapy functions by delivering radiation precisely to tumor cells through ligands that bind to specific receptors, thereby minimizing harm to healthy tissues and eradicating cancer cells internally. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023, equating to an average of 972 per day, which signifies an increase of 8,605 compared to 2022. Consequently, the increasing cancer incidence is driving the growth of the radioligand therapy market.

Which Segment Types Are Examined In The Radioligand Therapy Market Segment Study?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

What Trends Are Transforming The Radioligand Therapy Market?

Companies operating in the radioligand therapy market are focusing on developing advanced solutions, such as radioligand therapy facilities, to boost production efficiency and maintain high quality and safety standards in the manufacturing and distribution of targeted cancer treatments. These radioligand therapy facilities are specialized centers designed to manage and deliver radioactive drugs for targeted cancer treatment, utilizing advanced imaging systems and radiation shielding, while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.

Which Players Are Part Of The Competitive Landscape Of The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

Get The Full Radioligand Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Where Is The Radioligand Therapy Market Most Concentrated Geographically?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Radioligand Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company

Property Management Service Market Report 2026

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Radioligand Therapy Market Grow Between 2026 And 2030?

The radioligand therapy market has seen considerable growth in recent years. Its size is expected to expand from $6.63 billion in 2025 to $7.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.4%. This historical expansion can be attributed to several factors, including the limited availability of radioligands, reliance on conventional cancer therapies, growing awareness of targeted therapy benefits, increasing hospital adoption of nuclear medicine techniques, and regulatory approvals for early rlt drugs.

The radioligand therapy market size is anticipated to experience substantial growth in the coming years. It is projected to expand to $10.72 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 10.0%. This growth during the forecast period is attributable to the introduction of novel alpha and beta emitters, the expansion of combined emission therapies, integration with precision oncology, an increase in clinical trials for neurological and cardiovascular applications, and greater investment in home care and outpatient rlt services. Prominent trends for the forecast period include the increasing adoption of targeted radioligand therapy in oncology, the broadening of alpha and beta emitter-based therapies, the integration of radioligand therapy with personalized medicine approaches, the expansion of hospital and research institution-based rlt programs, and a heightened focus on minimizing side effects and improving patient outcomes.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Key Drivers Are Affecting The Radioligand Therapy Market Development?

The escalating incidence of cancer is projected to stimulate growth within the radioligand therapy market. Cancer is defined as a condition involving the unchecked proliferation of abnormal cells that can infiltrate surrounding tissues and disseminate throughout the body. The rise in cancer cases is attributed to sustained exposure to environmental pollutants, which harm DNA, impair cell function, and foster irregular cell development. Radioligand therapy functions by delivering radiation precisely to tumor cells through ligands that bind to specific receptors, thereby minimizing harm to healthy tissues and eradicating cancer cells internally. For instance, in October 2025, the National Health Service (NHS), a UK-based government health agency, reported 354,820 new cancer diagnoses in 2023, equating to an average of 972 per day, which signifies an increase of 8,605 compared to 2022. Consequently, the increasing cancer incidence is driving the growth of the radioligand therapy market.

Which Segment Types Are Examined In The Radioligand Therapy Market Segment Study?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

What Trends Are Transforming The Radioligand Therapy Market?

Companies operating in the radioligand therapy market are focusing on developing advanced solutions, such as radioligand therapy facilities, to boost production efficiency and maintain high quality and safety standards in the manufacturing and distribution of targeted cancer treatments. These radioligand therapy facilities are specialized centers designed to manage and deliver radioactive drugs for targeted cancer treatment, utilizing advanced imaging systems and radiation shielding, while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility is the largest and most advanced Novartis site dedicated to RLT, designed for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling substantial supply increases to meet growing patient demand in the US and Canada.

Which Players Are Part Of The Competitive Landscape Of The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

Get The Full Radioligand Therapy Market Report:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Where Is The Radioligand Therapy Market Most Concentrated Geographically?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Radioligand Therapy Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company

Property Management Service Market Report 2026

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Will The Market Size Of The Radioligand Therapy Market Evolve From 2026 To 2030?

The radioligand therapy market has experienced substantial expansion in recent years. Forecasts indicate that its valuation will rise from $6.63 billion in 2025 to $7.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this historical growth include the previously limited supply of radioligands, a past reliance on traditional cancer treatments, increasing recognition of the advantages of targeted therapies, greater integration of nuclear medicine practices in hospitals, and the granting of regulatory approvals for initial radioligand therapy drugs.

The radioligand therapy market size is anticipated to experience rapid expansion in the coming years. It is expected to reach $10.72 billion by 2030, growing at a compound annual growth rate (CAGR) of 10.0%. This projected growth during the forecast period can be attributed to the development of novel alpha and beta emitters, the expansion of combined emission therapies, integration with precision oncology, an increase in clinical trials for neurological and cardiovascular applications, and rising investment in home care and outpatient radioligand therapy services. Key trends for the forecast period include the increasing adoption of targeted radioligand therapy in oncology, the expansion of alpha and beta emitter-based therapies, the integration of radioligand therapy with personalized medicine approaches, the growth of hospital and research institution-based radioligand therapy programs, and a rising focus on minimizing side effects and enhancing patient outcomes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

What Drivers Are Influencing The Radioligand Therapy Market?

The rising occurrence of cancer is projected to propel the expansion of the radioligand therapy market going forward. Cancer is characterized by the uncontrolled proliferation of abnormal cells that can invade surrounding tissues and spread throughout the body. The increase in cancer incidence is attributed to long-term exposure to environmental pollutants, which damage DNA, disrupt cell function, and promote abnormal cell growth. Radioligand therapy treats cancer by directing radiation to tumor cells through ligands that bind to specific receptors, thereby minimizing harm to healthy tissues and destroying cancer cells internally. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, an average of 972 per day, which is 8,605 more than in 2022. Consequently, the increasing cancer incidence is driving the growth of the radioligand therapy market.

Which Segment Areas Are Covered In The Radioligand Therapy Market Analysis?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

What Key Developments And Trends Are Impacting The Radioligand Therapy Market?

Leading companies within the radioligand therapy market are focusing on developing sophisticated solutions, such as dedicated radioligand therapy facilities, to boost production efficiency and maintain consistent quality and safety standards in the manufacturing and distribution of precise cancer treatments. Radioligand therapy facilities are specialized centers built to handle and deliver radioactive drugs for targeted cancer treatment, utilizing advanced imaging systems and radiation shielding, all while ensuring safety through trained personnel and strict protocols. For instance, in January 2024, Novartis AG, a Switzerland-based pharmaceutical company, announced the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This plant received Food and Drug Administration (FDA) approval for commercial manufacturing. Spanning 70,000 square feet, this facility stands as Novartis’s largest and most advanced site dedicated to RLT, engineered for efficient, time-sensitive production, and includes plans for fully automated production lines, enabling significant increases in supply to meet growing patient demand in the US and Canada.

Which Global Companies Are Actively Competing In The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc.

Read the full radioligand therapy market report here:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Which Regions Are Expected To Experience Rapid Expansion In The Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Radioligand Therapy Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company

Property Management Service Market Report 2026

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the radioligand therapy market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Radioligand Therapy Market covering 2026–2035?

The radioligand therapy market size has seen significant growth in recent years. This market is expected to expand from $6.63 billion in 2025 to $7.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. The expansion observed in the past can be ascribed to several factors, including the constrained supply of radioligands, the previous dependence on standard cancer therapies, heightened understanding of the advantages of targeted therapy, increasing integration of nuclear medicine techniques by hospitals, and the granting of regulatory approvals for initial radioligand therapy drugs.

The radioligand therapy market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $10.72 billion, exhibiting a compound annual growth rate (CAGR) of 10.0%. This anticipated growth during the forecast period is driven by several factors, including the emergence of new alpha and beta emitters, the broadening scope of combined emission therapies, their integration with precision oncology, an increase in clinical trials targeting neurological and cardiovascular conditions, and greater investment in home care and outpatient rlt services. Key trends expected over the forecast period encompass the growing acceptance of targeted radioligand therapy in oncology, the proliferation of alpha and beta emitter-based treatments, the incorporation of radioligand therapy into personalized medicine strategies, an increase in rlt programs within hospitals and research institutions, and an intensified focus on reducing adverse effects while improving patient results.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Radioligand Therapy Market?

The rising incidence of cancer is anticipated to stimulate the expansion of the radioligand therapy market in the future. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells, which can infiltrate surrounding tissues and spread throughout the body. The escalation in cancer cases stems from prolonged exposure to environmental pollutants that damage DNA, disrupt cellular function, and encourage irregular cell growth. Radioligand therapy addresses cancer by precisely directing radiation to tumor cells through ligands that bind to specific receptors, thereby minimizing harm to healthy tissues and eradicating cancer cells internally. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, averaging 972 per day, which signifies 8,605 more than in 2022. Consequently, the increasing cancer incidence is a key factor propelling the growth of the radioligand therapy market.

What Leading Segments Are Studied In The Radioligand Therapy Market?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

Which Trends Are Guiding The Evolution Of The Radioligand Therapy Market?

Leading companies in the radioligand therapy market are concentrating on developing sophisticated solutions, specifically radioligand therapy facilities, to boost production efficiency and uphold consistent quality and safety standards throughout the manufacturing and distribution processes of targeted cancer treatments. Radioligand therapy facilities are specialized centers crafted for managing and delivering radioactive drugs for precise cancer treatment, employing advanced imaging systems and radiation shielding, all while guaranteeing safety through well-trained personnel and stringent protocols. For example, in January 2024, Novartis AG, a pharmaceutical company based in Switzerland, announced the automation of its new substantial radioligand therapy (RLT) production plant located in Indiana. This facility obtained Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility stands as Novartis’s largest and most advanced site dedicated to RLT, engineered for efficient, time-sensitive production, and encompasses plans for entirely automated production lines, which will facilitate considerable supply increases to meet the rising patient demand across the US and Canada.

Which Major Firms Are Strengthening Their Position In The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Radioligand Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company

Property Management Service Market Report 2026

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the radioligand therapy market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Radioligand Therapy Market covering 2026–2035?

The radioligand therapy market size has seen significant growth in recent years. This market is expected to expand from $6.63 billion in 2025 to $7.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. The expansion observed in the past can be ascribed to several factors, including the constrained supply of radioligands, the previous dependence on standard cancer therapies, heightened understanding of the advantages of targeted therapy, increasing integration of nuclear medicine techniques by hospitals, and the granting of regulatory approvals for initial radioligand therapy drugs.

The radioligand therapy market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $10.72 billion, exhibiting a compound annual growth rate (CAGR) of 10.0%. This anticipated growth during the forecast period is driven by several factors, including the emergence of new alpha and beta emitters, the broadening scope of combined emission therapies, their integration with precision oncology, an increase in clinical trials targeting neurological and cardiovascular conditions, and greater investment in home care and outpatient rlt services. Key trends expected over the forecast period encompass the growing acceptance of targeted radioligand therapy in oncology, the proliferation of alpha and beta emitter-based treatments, the incorporation of radioligand therapy into personalized medicine strategies, an increase in rlt programs within hospitals and research institutions, and an intensified focus on reducing adverse effects while improving patient results.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Radioligand Therapy Market?

The rising incidence of cancer is anticipated to stimulate the expansion of the radioligand therapy market in the future. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells, which can infiltrate surrounding tissues and spread throughout the body. The escalation in cancer cases stems from prolonged exposure to environmental pollutants that damage DNA, disrupt cellular function, and encourage irregular cell growth. Radioligand therapy addresses cancer by precisely directing radiation to tumor cells through ligands that bind to specific receptors, thereby minimizing harm to healthy tissues and eradicating cancer cells internally. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, averaging 972 per day, which signifies 8,605 more than in 2022. Consequently, the increasing cancer incidence is a key factor propelling the growth of the radioligand therapy market.

What Leading Segments Are Studied In The Radioligand Therapy Market?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

Which Trends Are Guiding The Evolution Of The Radioligand Therapy Market?

Leading companies in the radioligand therapy market are concentrating on developing sophisticated solutions, specifically radioligand therapy facilities, to boost production efficiency and uphold consistent quality and safety standards throughout the manufacturing and distribution processes of targeted cancer treatments. Radioligand therapy facilities are specialized centers crafted for managing and delivering radioactive drugs for precise cancer treatment, employing advanced imaging systems and radiation shielding, all while guaranteeing safety through well-trained personnel and stringent protocols. For example, in January 2024, Novartis AG, a pharmaceutical company based in Switzerland, announced the automation of its new substantial radioligand therapy (RLT) production plant located in Indiana. This facility obtained Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility stands as Novartis’s largest and most advanced site dedicated to RLT, engineered for efficient, time-sensitive production, and encompasses plans for entirely automated production lines, which will facilitate considerable supply increases to meet the rising patient demand across the US and Canada.

Which Major Firms Are Strengthening Their Position In The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Radioligand Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company

Property Management Service Market Report 2026

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the radioligand therapy market from 2026–2035 with trusted insights from The Business Research Company

What long-term size projections exist for the Radioligand Therapy Market covering 2026–2035?

The radioligand therapy market size has seen significant growth in recent years. This market is expected to expand from $6.63 billion in 2025 to $7.32 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 10.4%. The expansion observed in the past can be ascribed to several factors, including the constrained supply of radioligands, the previous dependence on standard cancer therapies, heightened understanding of the advantages of targeted therapy, increasing integration of nuclear medicine techniques by hospitals, and the granting of regulatory approvals for initial radioligand therapy drugs.

The radioligand therapy market is projected to experience substantial expansion in the coming years. By 2030, this market is anticipated to reach a valuation of $10.72 billion, exhibiting a compound annual growth rate (CAGR) of 10.0%. This anticipated growth during the forecast period is driven by several factors, including the emergence of new alpha and beta emitters, the broadening scope of combined emission therapies, their integration with precision oncology, an increase in clinical trials targeting neurological and cardiovascular conditions, and greater investment in home care and outpatient rlt services. Key trends expected over the forecast period encompass the growing acceptance of targeted radioligand therapy in oncology, the proliferation of alpha and beta emitter-based treatments, the incorporation of radioligand therapy into personalized medicine strategies, an increase in rlt programs within hospitals and research institutions, and an intensified focus on reducing adverse effects while improving patient results.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

Which Drivers Are Impacting The Competitive Landscape Of The Radioligand Therapy Market?

The rising incidence of cancer is anticipated to stimulate the expansion of the radioligand therapy market in the future. Cancer is a condition characterized by the uncontrolled proliferation of abnormal cells, which can infiltrate surrounding tissues and spread throughout the body. The escalation in cancer cases stems from prolonged exposure to environmental pollutants that damage DNA, disrupt cellular function, and encourage irregular cell growth. Radioligand therapy addresses cancer by precisely directing radiation to tumor cells through ligands that bind to specific receptors, thereby minimizing harm to healthy tissues and eradicating cancer cells internally. For instance, in October 2025, according to the National Health Service (NHS), a UK-based government health agency, there were 354,820 new cancer diagnoses in 2023, averaging 972 per day, which signifies 8,605 more than in 2022. Consequently, the increasing cancer incidence is a key factor propelling the growth of the radioligand therapy market.

What Leading Segments Are Studied In The Radioligand Therapy Market?

The radioligand therapy market covered in this report is segmented –

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

Which Trends Are Guiding The Evolution Of The Radioligand Therapy Market?

Leading companies in the radioligand therapy market are concentrating on developing sophisticated solutions, specifically radioligand therapy facilities, to boost production efficiency and uphold consistent quality and safety standards throughout the manufacturing and distribution processes of targeted cancer treatments. Radioligand therapy facilities are specialized centers crafted for managing and delivering radioactive drugs for precise cancer treatment, employing advanced imaging systems and radiation shielding, all while guaranteeing safety through well-trained personnel and stringent protocols. For example, in January 2024, Novartis AG, a pharmaceutical company based in Switzerland, announced the automation of its new substantial radioligand therapy (RLT) production plant located in Indiana. This facility obtained Food and Drug Administration (FDA) approval for commercial manufacturing. This 70,000-square-foot facility stands as Novartis’s largest and most advanced site dedicated to RLT, engineered for efficient, time-sensitive production, and encompasses plans for entirely automated production lines, which will facilitate considerable supply increases to meet the rising patient demand across the US and Canada.

Which Major Firms Are Strengthening Their Position In The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Novartis AG, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Telix Pharmaceuticals, Mariana Oncology Inc., AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C-Ray Therapeutics Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

Which Region Shows The Strongest Potential For Future Expansion In The Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Radioligand Therapy Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2026, By The Business Research Company

Property Management Service Market Report 2026

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Real Estate Rental Market Report 2026

https://www.thebusinessresearchcompany.com/report/real-estate-rental-global-market-report

Financial Accounting Advisory Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the radioligand therapy market from 2025–2034 with trusted insights from The Business Research Company

What Are The Market Size Estimates For The Radioligand Therapy Market?

The radioligand therapy market has witnessed rapid expansion in recent years. This market is anticipated to increase from $6.01 billion in 2024 to $6.64 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 10.5%. The historical growth of this market can be attributed to several factors, including the rising utilization of liquid biopsy, the advent of tumor-agnostic therapies, the integration of artificial intelligence within oncology, a growing pipeline of bispecific antibodies, and an increase in government funding directed towards cancer initiatives.

The radioligand therapy market is poised for significant expansion in the coming years. It is forecast to reach $9.77 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 10.2%. This growth over the forecast period stems from factors such as increasing investments by large pharmaceutical firms in oncology startups, greater use of real-world evidence, advancements in radiopharmaceutical and theranostics research, expanding collaborations between academic and industrial sectors, and the rising incidence of rare and orphan cancers. Prominent trends for the forecast duration encompass AI-driven radiopharmaceutical design, theranostics featuring dual imaging-therapy platforms, microfluidics-based radiotracer synthesis, the development of next-generation alpha-emitting isotopes, and the deployment of 3D-printed personalized dosimetry devices.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27403&type=smp

What Drivers Are Accelerating Expansion Of The Radioligand Therapy Market?

Rising occurrences of cancer are projected to stimulate expansion within the radioligand therapy market. Cancer is defined as a condition characterized by the unchecked proliferation of atypical cells, capable of infiltrating adjacent tissues and disseminating across the body. The prevalence of cancer is escalating, attributed to prolonged contact with environmental contaminants that harm DNA, impair cellular processes, and foster irregular cell development. Radioligand therapy provides a cancer treatment method by delivering radiation directly to tumor cells using ligands that attach to particular receptors, thereby reducing damage to healthy tissues and eradicating cancer cells from within. For example, in January 2022, data from the American Cancer Society, a US-based non-profit organization focused on cancer awareness, projected approximately 1.9 million new cancer diagnoses and 609,360 cancer-attributed fatalities in the US, translating to roughly 1,670 deaths per day. Consequently, the heightened occurrence of cancer is propelling the expansion of the radioligand therapy market.

What Are The Key Segment Trends Observed In The Radioligand Therapy Market?

The radioligand therapy market covered in this report is segmented

1) By Type Of Radioligand: Alpha Emitters, Beta Emitters, Auger Emitters, Combined Emissions

2) By Molecular Target: Hormone Receptors, Growth Factor Receptors, Antigen Tumor Markers, Other Molecular Targets

3) By Route Of Administration: Intravenous (IV), Intramuscular (IM), Subcutaneous, Oral

4) By Application: Oncology, Cardiovascular Disorders, Neurological Disorders, Infectious Diseases

5) By End-User: Hospitals, Diagnostic Laboratories, Research Institutions, Home Care Settings

Subsegments:

1) By Alpha Emitters: Actinium-225 (Ac-225), Radium-223 (Ra-223), Astatine-211 (At-211), Bismuth-213 (Bi-213)

2) By Beta Emitters: Lutetium-177 (Lu-177), Iodine-131 (I-131), Yttrium-90 (Y-90), Samarium-153 (Sm-153)

3) By Auger Emitters: Iodine-125 (I-125), Indium-111 (In-111), Gallium-67 (Ga-67), Thallium-201 (Tl-201)

4) By Combined Emissions: Terbium-161 (Tb-161), Copper-67 (Cu-67), Rhenium-186 (Re-186), Lead-212 (Pb-212)

Which Disruptive Trends Are Driving Change Across The Radioligand Therapy Market?

Major companies in the radioligand therapy market are prioritizing the development of advanced solutions, such as specialized radioligand therapy facilities, to boost production efficiency and uphold consistent quality and safety standards in the manufacturing and distribution of targeted cancer treatments. These radioligand therapy facilities are dedicated centers designed for the handling and delivery of radioactive drugs for targeted cancer treatment, utilizing sophisticated imaging systems and radiation shielding, while ensuring safety through trained staff and stringent protocols. For instance, in January 2024, Novartis AG, a pharmaceutical company based in Switzerland, disclosed the automation of its new large-scale radioligand therapy (RLT) production plant in Indiana. This facility has secured Food and Drug Administration (FDA) approval for commercial manufacturing. Covering 70,000-square-foot, this site is Novartis’s largest and most advanced facility exclusively for RLT, structured for efficient, time-sensitive production, and includes strategies for fully automated production lines, enabling significant increases in supply to meet rising patient demand in the US and Canada.

Who Are The Major Stakeholders Operating In The Radioligand Therapy Market?

Major companies operating in the radioligand therapy market are Bayer AG, Novartis AG, Eli Lilly and Company, Lantheus Holdings Inc., Curium LLC, Eckert & Ziegler Strahlen- und Medizintechnik AG, Molecular Partners AG, Telix Pharmaceuticals, Nanobiotix S.A., Mariana Oncology Inc., Artios Pharma Limited, AdvanCell Pty Ltd., Evergreen Theragnostics Inc., Fusion Pharmaceuticals Inc., RadioMedix Inc., Ariceum Therapeutics GmbH, Radiopharm Theranostics Limited, Convergent Therapeutics Inc., C‑Ray Therapeutics Inc., OncoSil Medical Ltd.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/radioligand-therapy-global-market-report

What Regional Factors Are Accelerating Growth In The Radioligand Therapy Market?

North America was the largest region in the radioligand therapy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the radioligand therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=27403&type=smp

Browse Through More Reports Similar to the Global Radioligand Therapy Market 2025, By The Business Research Company

Property Management Service Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/property-management-service-global-market-report

Financial Accounting Advisory Services Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/financial-accounting-advisory-services-global-market-report

Real Estate Agency And Brokerage Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/real-estate-agency-and-brokerage-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model